Leverage Industry Case Studies in Robust Model Validation for Regulatory Use & Establish Reproducibility to Optimize Complex In Vitro Models for Discovery, Translational, Efficacy & Safety Studies

Following the FDA’s introduction of the Modernization Act 3.0 and the latest guidance on new approach methods (NAMs), GSK developing a new lung organoid model to empower pulmonary fibrosis research, and Merck acquiring HUB Organoids to enable more effective drug development and reduce reliance on animal testing, it’s an exciting time for pharma and biotech to leverage complex in vitro models in drug discovery and development.

Despite this growth, challenges persist in standardizing protocols for model validation, safeguarding model reproducibility while ensuring scalability, and understanding what data regulators will accept.

Built by biopharma-for-biopharma, the 10th 3D Tissue Models Summit returned to unite ‘front-line’ experts to share practical case studies on validating, improving reproducibility, and interrogating regulatory requirements for complex in vitro models in drug discovery and development.

The only intimate, industry-focussed forum to stay abreast on how to confidently harness various complex in vitro models to transform your own discovery and development workflows and empower clinical translatability.